The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations

Neuroscience Letters

Volumn 249, Issue 2-3, 1998, Pages 115-118

  Crawford, F ^a   Fallin, D ^a   Suo, Z ^a   Abdullah, L ^a   Gold, M ^a   Gauntlett, A ^a   Duara, R ^b   Mullan, M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Alzheimer's Disease; Apolipoprotein E; Butyrylcholinesterase; Genetic association; K variant

Indexed keywords

APOLIPOPROTEIN E; CHOLINESTERASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BUTYRYLCHOLINESTERASE; COMMUNITY HEALTH CENTERS; FEMALE; GENOTYPE; HUMANS; MALE; ODDS RATIO;

EID: 0032547037     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00423-6     Document Type: Article

References (20)

1. Cai X., Stanton J., Fallin D., Hoyne J., Duara R., Gold M., Sevush S., Scibelli P., Crawford F., Mullan M. No association between the intronic preselnilin-1 polymorphism and Alzheimer's disease in clinic and population-based samples. Am. J. Med. Genet. (Neuropsychiatric genet.). 74:1997;202-203.
2. Chung H., Roberts C., Greenberg S., Rebeck W., Christie R., Wallace R., Jacob H., Hyman B. Lack of association of trinucleotide repeat polymorphisms in the very-low-density lipoprotein receptor gene with Alzheimer's disease. Ann. Neurol. 6:1996;800-803.
3. Fallin D., Reading S., Schinka J., Hoyne J., Scibelli P., Gold M., Crawford F., Mullan M. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease. Am. J. Med. Genet. 74(2):1997;192-194.
4. Fallin D., Gauntlett A., Scibelli P., Cai X., Duara R., Gold M., Crawford F., Mullan M. No association between the VLDL-R gene and late-onset Alzheimer's disease nor interaction with the APOE gene in population-based and clinic samples. Genet. Epidemiol. 14:1997;299-305.
5. Fallin D., Kundtz A., Town T., Gauntlett A., Duara R., Barker W., Crawford F., Mullan M. No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample. Neurosci. Lett. 233:1997;145-147.
6. Gomez-Ramos P., Bouras C., Moran M. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients. Brain Res. 640:1994;17-24.
7. Guillozet A., Smiley J., Mash D., Mesulam M. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol. 42(6):1997;909-918.
8. Jensen F., Nielsen L., Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum. Hered. 46:1996;26-31.
9. Kamboh M., Sanghera D., Rerrell R., DeKosky S. APOE 4-associated Alzheimer's disease risk is modified by alpha-1-antichymotrypsin polymorphism. Nat. Genet. 10:1995;486-488.
10. La Du B.N., Bartels C.F., Nogueira C.P., Hajra A., Lightstone H., Van der Spek A., Lockridge O. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. Clin. Biochem. 23(5):1990;423-431.
11. Lehmann D.J., Johnston C., Smith A.D. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 6(11):1997;1933-1936.
12. Lendon C., Talbot C., Craddock N., Jan S.W., Wragg M., Morris J., Goate A. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci. Lett. 222:1997;187-190.
13. Mesulam M., Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 31:1994;722-727.
14. Mullan M., Scibelli P., Duara R., Fallin D., Gold M., Schinka J., Hoyne J., Osborne A., Sevush S., Crawford F. Familial and population-based studies of apolipoprotein E and Alzheimer's disease. Ann. NY. Acad. Sci. 802:1996;16-26.
15. National Institute of Aging/Alzheimer's Association Working Group, Apolipoprotein E Genotyping in Alzheimer's Disease, Lancet, 347 (1996) 1091-1095.
16. Okuizumi K., Onedera O., Seki K., Namba Y., Ikeda K., Yamamoto T., Seki K., Ueki A., Nanko S., Tanaka H., Takahashi H., Oyanagi K., Mizusawa H., Kanazawa I., Tsuji S. Genetic association of very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat. Genet. 11:1995;207-209.
17. Pritchard M.L., Saunders P.C., Gaskell G.W., Small G.W., Conneally P.M., Rosi B., Yamaoka L.H., Rose A.D., Haines J.L., Pericak-Vance M.A., Risch N. No association between very low density lipoprotein receptor (VLDL-R) and Alzheimer's disease in American Caucasians. Neurosci Lett. 209:1996;105-108.
18. Strittmatter W.H., Saunders A.M., Schmechel D., Pericak Vance M., Enghild I., Salvesen G., Roses A. Apolipoprotein E: high avidity binding to β-amyloid and increased frequency of type 4 allele in late onset Alzheimer's Disease. Proc. Natl. Acad Sci. (USA). 90:1993;1977-1981.
19. Wenham P., Price W., Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet. 337:1991;1158-1159.
20. Wragg M., Hutton M., Talbot C. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Alzheimer's Disease Collaborative Group. Lancet. 347:1996;509-512.